Actor portrayals

THE BENEFITS OF TREATING HD CHOREA WITH ONE‑CAPSULE, ONCE‑DAILY INGREZZA

Actor portrayals

INGREZZA TAKES HD CHOREA CONTROL A STEP FORWARD

80% began experiencing improvement in just 2 weeks*, Graphic

In the clinical study, most people began to experience improvement at 2 weeks.* Significant improvement was shown at 12 weeks vs placebo.

* In a post-clinical study evaluation, 51 of 64 patients (80%) taking INGREZZA 40 mg had at least a 1-point reduction in TMC score at 2 weeks vs before treatment, vs 43 of 60 (72%) for those taking placebo.

INGREZZA was studied in a 12-week clinical trial. A total of 128 patients participated in the study. Results were based on 64 patients taking INGREZZA 40 mg, 60 mg, or 80 mg. The primary efficacy endpoint was change in TMC from the baseline to maintenance periods.


INGREZZA SIGNIFICANTLY IMPROVED HD CHOREA

People taking INGREZZA experienced greater HD chorea improvement vs placebo as measured by TMC score

Most people taking INGREZZA experienced clinically meaningful improvement at 12 weeks§

HD Chorea improvement, INGREZZA® vs placebo, Graphic

People taking INGREZZA experienced greater HD chorea improvement vs placebo as measured by TMC score

Most people taking INGREZZA experienced clinically meaningful improvement at 12 weeks§


4.6-point improvement seen with INGREZZA (n=58) vs 1.4 with placebo (n=54) in TMC score from the start to the end of the 12-week clinical study.

§ Most patients (57%) experienced clinically meaningful improvements, defined as a 4-point or greater change in TMC score.


SIGNIFICANTLY MORE PATIENTS AND HEALTHCARE PROVIDERS REPORTED IMPROVEMENT WITH INGREZZA

53% of people

in the clinical study reported their overall HD chorea as “very much improved” or “much improved” with the help of INGREZZA vs 26% for placebo at 12 weeks.

HD Chorea very much improved or much improved reported by 53% of people vs. 26% placebo, Graphic

53% of patients (29/55) taking INGREZZA vs 26% of those taking placebo (14/53), based on patient-reported chorea severity scale (PGI-C scale) at 12 weeks vs before treatment.

43% of healthcare professionals

in the clinical study reported HD chorea as “very much improved” or “much improved” with the help of INGREZZA vs 13% for placebo at 12 weeks.

43% of health care professionals reported HD Chorea as very much improved or much improved vs 13% for placebo, Graphic

43% of patients (24/56) taking INGREZZA vs 13% of those taking placebo (7/53) based on clinician-reported chorea severity (CGI-C scale) at 12 weeks vs before treatment.

53% of patients (29/55) taking INGREZZA vs 26% of those taking placebo (14/53), based on patient-reported chorea severity scale (PGI-C scale) at 12 weeks vs before treatment.

43% of patients (24/56) taking INGREZZA vs 13% of those taking placebo (7/53) based on clinician-reported chorea severity (CGI-C scale) at 12 weeks vs before treatment.

Learn more about the INGREZZA clinical study

128 PEOPLE enrolled

64 PEOPLE
randomly selected
to take INGREZZA

64 PEOPLE
randomly selected
to take placebo

The goal of the study was to see if people taking INGREZZA experienced improvements in their HD chorea as measured by changes in TMC (Total Maximal Chorea) score. Approximately 120 people who completed the study were then enrolled in a 3-year extension to evaluate the long-term safety and effectiveness of INGREZZA in the treatment of HD chorea.


Actor portrayal

Learn about the potential side effects of INGREZZA

Actor portrayal

HD Chorea capsule, Icon

PEOPLE TAKING INGREZZA CAN STAY ON MOST OF THEIR STABLE MENTAL HEALTH MEDICATIONS

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Ready to take HD chorea control a step forward?

The Doctor Discussion Guide has tips for talking to a healthcare provider about your uncontrollable movements and HD chorea treatment options.

Download Guide
Email Guide
Please enter a valid email address.

Your email address will be used only for the purpose of sending the PDF and will not be stored.

Your Doctor Discussion Guide has been sent.

Send to another email

Actor portrayal

Here’s why INGREZZA is unlike other medications approved to treat HD chorea

Actor portrayal

INGREZZA offers simple dosing that's always one capsule, once daily

You are now leaving
Ingrezza.com

Neurocrine Biosciences, Inc. is not responsible for the content of linked third-party websites. Please be aware that the privacy policies and terms of use on these sites are different from Neurocrine Biosciences, Inc. policies.

Leave site